Chengdu Huarenkang Biotechnology Co., Ltd., established in 2020 with a registered capital of RMB 200 million, is a wholly-owned subsidiary of Chengdu Maxvax Biotechnology. Focusing on the development of innovative human vaccines, it is an important research and development base of the group company in Southwestern China.
